KCT0007595已完成未知
A Phase I study of autologous WT1-specific CD8+ T cell immunotherapy in patients with advanced solid tumors who failed standard therapy
ational Cancer Center0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1) Men and women between the ages of 18 and 75
- •2) In the case of a histologically or cytologically confirmed advanced solid cancer patients who fails to respond to standard treatment or cannot be treated
- •3) WT1 antigen epitope screening test must be passed
- •4) Performance Status Score Karnofsky performance status must be = 50 or ECOG Scale must be =< 2
- •5) Expected survival period of at least 12 weeks
- •6) Patients who have listened to the explanation before the trial and voluntarily consented in writing by the patient or his/her representative
排除标准
- •1) Performance Status Score (Karnofsky performance status < 50) or ECOG > 2
- •2) History of surgery, radiation therapy, or chemotherapy within 3 weeks of trial registration
- •3) The following test results
- •- Absolute neutrophil count <1,000/µL
- •- Platelet count <75,000/µL
- •- Hemoglobin <10 g/dL
- •- Serum creatinine >2.0 mg/dL
- •- AST/ALT >3 x upper limit of normal range (ULN)
- •- Total bilirubin >2.0 mg/dL
- •- prothrombin time >1.5 x ULN
- •4) If there was an increase in the steroid dose at least 2 weeks before registration
- •5) Clinically significant active cardiovascular disease, including:
- •Uncontrolled hypertension (i.e., systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg), unstable angina, pulmonary embolism, cerebrovascular disease, valvular disease, congestive heart failure, or myocardial infarction within the past 6 months, or serious cardiac arrhythmias
- •6) Anti-HIV antibody positive patient
- •7) Patients with confirmed tuberculosis infection within 1 year. However, patients who have been cured for 6 months after treatment are included in the clinical trial.
- •8) Patients with autoimmune disease or inflammatory disease
- •9) If you are taking immunosuppressants other than steroids, you must stop 3 weeks before registration.
- •10) active infection
- •11) Patients with serious medical conditions that may interfere with other clinical trials
- •12) Patients who have received other investigational drugs within 3 weeks of trial registration
- •13) Patients who have previously received cultured immune cells
- •14) Pregnant, or breastfeeding
- •15) Women or men of childbearing age who do not want to use effective contraceptive methods
- •16) Patients with dementia or significant psychiatric or social problems that may limit their understanding or interfere with the performance of the requirements of the subject consent form and clinical trial protocol
研究者
相似试验
招募中
不适用
Clinical trial of autologous tumor-specific T cellsNeoplasmsKCT0004064CC Hospital24
已完成
1 期
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent SarcomaHLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Myxoid LiposarcomaRecurrent Synovial SarcomaNCT03450122M.D. Anderson Cancer Center15
已完成
1 期
Fhase I clinical study of WT1 petide-based immnotherapy using WT1 helper peptide for recurrent malignant gliomaRecurrent malignant gliomaJPRN-UMIN000003506Department of Cancer immunotherapy, Osaka University Graduate School of Medicine18
已完成
不适用
Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantatioAcute myeloid or lymphoid leukemia malignant lymphoma multiple myelomaJPRN-UMIN000004753Osaka University6
招募中
1 期
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantMixed Phenotype Acute LeukemiaChronic Myelomonocytic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeMyelodysplastic SyndromeRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Myelodysplastic SyndromeRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Myelodysplastic SyndromeRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaJuvenile Myelomonocytic LeukemiaAcute Undifferentiated LeukemiaMinimal Residual DiseaseAcute Biphenotypic LeukemiaChronic Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaLeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMinimal Residual DiseaseMixed Phenotype Acute LeukemiaLeukemiaAcute Myeloid LeukemiaJuvenile Myelomonocytic LeukemiaAcute Undifferentiated LeukemiaNCT03326921Fred Hutchinson Cancer Center24